Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Amy Ayers
Evaluation of gene expression assays to classify large B-cell lymphoma by molecular subtype using formalin-fixed paraffin-embedded tumor biopsies
Abstract Gene expression profiling (GEP) can classify large B-cell lymphoma (LBCL) into activated B-cell (ABC), dark zone signature (DZsig), and germinal center B-cell (GCB) subtypes, which can inform prognosis and treatment strategies.
Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study
|
Abstract Treatment strategies for relapsed/refractory large B-cell lymphoma (R/R LBCL) have evolved rapidly, yet relationships between therapy selection and outcomes remain poorly defined. The LEO CReWE study evaluated disease characteristics, patterns of care, and outcomes in 1504 patients with R/R LBCL from 2002 to 2022. Of these, 64% received chemoimmunotherapy at second-line (2L).
By Jean L. Koff, Melissa Larson, Jonathon Cohen, Izidore S. Lossos, Peter Martin, Thomas M Habermann, Carla Casulo, Samuel Yamshon, Andrea Lo-Rossi, Connie Lee Batlevi, Anthony Masaquel, Yong Mun, Yucai Wang, Arushi Khurana, Grzegorz Nowakowski, Dai Chihara, Eric Mou, Umar Farooq, Dilan A. Patel, Amy Ayers, James R. Cerhan, Christopher Flowers, Matthew J. Maurer, Loretta J Nastoupil, Ashwini Shewade, Tanner W. Reicks
|
Nature
Verified
Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma Original
|
Dear Editor, Despite recent advances in the treatment of systemic aggressive B-cell non-Hodgkin lymphomas (B-NHL), central nervous system (CNS) involvement remains a therapeutic challenge and is associated with dismal outcomes [1]. Chimeric antigen receptor (CAR) T-cell therapy achieves high overall response rates (ORR) in patients with CNS involvement, but responses are often short-lived (1-year progression-free survival (PFS) of 16–48%) [2,3,4,5].
By Karan L. Chohan, James Godfrey, Lorenzo Falchi, Manali K. Kamdar, Ajay Major, Wendy O. Dixon, Jennifer Crombie, Reid W. Merryman, Gilles Salles, Amy Ayers, Ayushi Chauhan, Alex Herrera, Álex Herrera, Geoffrey Shouse, Sairah Ahmed, Yazeed Sawalha, Rina L. Welkie, Steven Bair, Sonia Godbole, Omnia Farahat
|
Nature
Verified
Clinical trial access after CAR T‐cell therapy failure in relapsed/refractory large B‐cell lymphoma
CONFLICT OF INTEREST STATEMENT S.A. receives research funding from Nektar, Merck, Xencor, Chimagen and Genmab, KITE/Gilead, Janssen and Caribou and serves as a consultant for ADC therapeutics, KITE/Gilead, Genmab and BMS. P.S. receives research funding from Sobi, AstraZeneca-Acerta, ALX Oncology, Kite Gilead and ADC Therapeutics and serves as a consultant for Roche-Genentech, Abbvie-Genmab, Beigene, Ipsen, Kite/Gilead, AstraZeneca-Acerta, ADC Therapeutics, Sobi and Incyte.
Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐GemOx: A Multicenter Cohort Study
Conflicts of Interest S.Y. reports consulting fees from Bristol Meyers Squibb; reports support for attending meetings and/or travel from Bristol Meyers Squibb; reports participation on a Data Safety Monitoring Board or Advisory Board with Kite Pharma. J.L.K. reports consulting fees from BeiGene USA, AbbVie; reports research funding from Viracta Therapeutics, OncTernal Therapeutics, Atara Biotherapeutics. M.C.L. reports research funding from Genentech, Genmab.
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma
1 Introduction In recent decades, outcomes for patients with indolent non-Hodgkin lymphoma (iNHL) have improved with studies showing similar overall survival (OS) to healthy age-matched controls [1]; however, a subset of patients with iNHL (10%–30%) [2, 3] undergo transformation to an aggressive large B-cell lymphoma (aLBCL) and represent a high-risk patient subset with inferior OS [4].
Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for NHL
Abstract Prior studies have demonstrated that certain populations including older patients, racial/ethnic minority groups, and women are underrepresented in clinical trials. We performed a retrospective analysis of patients with non-Hodgkin lymphoma (NHL) seen at MD Anderson Cancer Center (MDACC) to investigate the association between trial participation, race/ethnicity, travel distance, and neighborhood socioeconomic status (nSES).
Real‐world analysis of safety and efficacy of CAR T‐cell therapy in lymphoma patients with decreased kidney function
Corresponding Author Sairah Ahmed Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Correspondence Sairah Ahmed, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Email: sahmed3@mdanderson.org Search for more papers by this author
Clinical Presentation and Outcome Differences Between Black Patients and Patients of Other Races and Ethnicities With Mycosis Fungoides and Sézary Syndrome | Dermatology | JAMA Dermatology | JAMA Network
Key Points Question What are the clinical features and outcomes for Black patients with mycosis fungoides and Sézary syndrome (MF/SS)? Findings This cohort study of 566 patients with MF/SS found that Black patients had high-risk baseline clinical features and an increased risk of progression to a higher cancer stage compared with patients of other races and ethnicities, though no difference in survival.
Racial differences in clinical presentation and outcomes in mycosis fungoides and Sézary syndrome in the United States: a large singe center retrospective analysis
Pamela Blair Allen, MD Pamela Blair Allen Affiliations Department of Hematology & Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, United States Search for articles by this author Subir Goyal Subir Goyal Affiliations Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, United States Search for articles by this author Colin O’Leary Amy Ayers Tim Niyogusaba Mohammad K.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Amy
Contact Amy, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack